Novel transcatheter arterial embolization for treatment of knee osteoarthritis: a randomized sham-controlled clinical trial

Novel transcatheter arterial embolization for treatment of knee osteoarthritis: a randomized sham-controlled clinical trial - Transcatheter arterial embolization treatment of knee osteoarthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON50381

Enrollment

Registered

2018-11-29

Start date

2019-06-05

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

degeneration of joint cartilage

Interventions

One group (n=29) undergoes transcatheter arterial embolization of neovessels around the knee and the other group (n=29) undergoes placebo- embolization.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age * 18 years - Knee pain for a duration of *6 months - Knee pain (numeric rating scale *4 - *8) on at least half of the days in the preceding month at time of inclusion - There is insufficient response of conservative treatment for at least 6 months - Radiographic knee osteoarthritis (radiographic Kellgren and Lawrence grade 1-3)

Exclusion criteria

Exclusion criteria: - Contra-indications for MRI (e.g. metallic foreign bodies, etc.) - Contra-indications for angiography - Renal insufficiency, checked with blood sample test (GFR

Design outcomes

Primary

Measure	Time frame
Change of pain (measured with Knee injury and Osteoarthritis Outcome Score) between baseline and 4 months follow-up.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 1, 2026